Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine

Background: Two doses of anti-SARS-CoV-2 mRNA-based vaccines are poorly immunogenic in solid organ transplant recipients (SOT). Methods: In total, 68 belatacept-treated SOT recipients followed at the Toulouse University Hospital were investigated. They were given three injections of the BNT162b2 mRN...

Descripción completa

Detalles Bibliográficos
Autores principales: Abravanel, Florence, Marion, Olivier, Del Bello, Arnaud, Beunon, Thomas, Romieu-Mourez, Raphaelle, Couat, Chloé, Pucelle, Mélanie, Staes, Laetitia, Guitard, Joelle, Esposito, Laure, Faguer, Stanislas, Kamar, Nassim, Izopet, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949272/
https://www.ncbi.nlm.nih.gov/pubmed/35334985
http://dx.doi.org/10.3390/vaccines10030354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949272/
https://www.ncbi.nlm.nih.gov/pubmed/35334985
http://dx.doi.org/10.3390/vaccines10030354

Ejemplares similares